Details of Disease

General Information of Disease (ID: DISAJOUO)

• Disease Name: Chronic eosinophilic leukemia
• Synonyms: CELNOS; CEL/hypereosinophilic syndrome; eosinophilic leukemia; chronic eosinophilic leukemia/hypereosinophilic syndrome; eosinophilic leukaemia; chronic eosinophilic leukemia; CEL
• Disease Hierarchy:
  DIS0C4XI: Chronic leukemia
  DIS5KAPA: Myeloproliferative neoplasm
  DISAJOUO: Chronic eosinophilic leukemia
• Disease Identifiers:
  MONDO ID: MONDO_0015687
  UMLS CUI: C0346421
  MedGen ID: 91106
  Orphanet ID: 168940
  SNOMED CT ID: 188733003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Imatinib	DM7RJXL	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
IL5	TTPREZD	Limited	Biomarker	[2]
IL5RA	TTXH9AD	Limited	Biomarker	[2]
PDGFRB	TTI7421	Disputed	Biomarker	[3]
PDGFRA	TT8FYO9	Strong	Biomarker	[4]

This Disease Is Related to 11 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
PCM1	OTFM133C	Limited	Genetic Variation	[5]
RRAGA	OTKISLG4	Limited	Biomarker	[2]
CCDC88C	OTIU02BS	Strong	Biomarker	[6]
CCL25	OTLWJ8CJ	Strong	Biomarker	[7]
CDK5RAP2	OTRKEVTY	Strong	Genetic Variation	[8]
FIP1L1	OTF91GTL	Strong	Biomarker	[9]
GCC2	OTT5I9FM	Strong	Biomarker	[3]
GPR160	OTMXJT73	Strong	Biomarker	[10]
NELL2	OTS4MJZ7	Strong	Biomarker	[11]
PIAS1	OTZVAHZI	Strong	Biomarker	[9]
SIGLEC8	OTQ5TRRV	Strong	Biomarker	[12]

References

• [1] Imatinib FDA Label
• [2] Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL.Oncotarget. 2016 Aug 19;8(39):64984-64998. doi: 10.18632/oncotarget.11401. eCollection 2017 Sep 12.
• [3] A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).Mol Genet Genomic Med. 2019 Apr;7(4):e00591. doi: 10.1002/mgg3.591. Epub 2019 Jan 29.
• [4] Cutaneous T-Cell Lymphoma, a Novel Manifestation of PDGFRA-Rearranged Neoplasm.Am J Dermatopathol. 2018 Aug;40(8):610-613. doi: 10.1097/DAD.0000000000001121.
• [5] t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.PLoS One. 2013;8(1):e53767. doi: 10.1371/journal.pone.0053767. Epub 2013 Jan 23.
• [6] Extramedullary molecular evidence of the 5'KIAA1509/3'PDGFRB fusion gene in chronic eosinophilic leukemia.Leuk Res. 2008 Feb;32(2):347-51. doi: 10.1016/j.leukres.2007.06.016. Epub 2007 Aug 2.
• [7] Human eosinophils show chemotaxis to lymphoid chemokines and exhibit antigen-presenting-cell-like properties upon stimulation with IFN-gamma, IL-3 and GM-CSF.Int Arch Allergy Immunol. 2008;146(3):227-34. doi: 10.1159/000115891. Epub 2008 Feb 11.
• [8] Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.Genes Chromosomes Cancer. 2006 Oct;45(10):950-6. doi: 10.1002/gcc.20359.
• [9] Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities.Cancer Sci. 2017 Feb;108(2):200-207. doi: 10.1111/cas.13129.
• [10] Cloning, chromosomal localization, and RNA expression of a human beta chemokine receptor-like gene.DNA Cell Biol. 1995 Aug;14(8):673-80. doi: 10.1089/dna.1995.14.673.
• [11] Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2.Leuk Lymphoma. 2007 Oct;48(10):1997-2007. doi: 10.1080/10428190701534424.
• [12] Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression.J Clin Immunol. 2011 Dec;31(6):1045-53. doi: 10.1007/s10875-011-9589-4. Epub 2011 Sep 22.